Using a virus to improve breast cancer treatment with immune therapies
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
This study is testing a new way to boost the effectiveness of current immune therapies for triple negative breast cancer by using a special virus that helps the immune system fight the cancer better, and it’s designed for patients who are looking for improved treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Endeavor Health Clinical Operations NIH-funded |
| Lab location | 1 site (Evanston, United States) |
| Project ID | NIH-11057511 on NIH RePORTER |
What this research studies
This research investigates a novel approach to enhance the effectiveness of existing immune therapies for triple negative breast cancer (TNBC) by using an oncolytic adenovirus that targets TGFβ, a protein that suppresses the immune response. The study aims to deliver this virus systemically to patients, which could help overcome resistance to current treatments like anti-PD-1 and anti-CTLA-4 therapies. By inhibiting TGFβ pathways, the goal is to create a more favorable tumor environment for immune attack. Patients may receive this treatment in conjunction with standard therapies to improve their outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have not responded to existing immune therapies.
Not a fit: Patients with non-triple negative breast cancer or those who have not yet undergone immune therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment responses for patients with triple negative breast cancer who currently have limited options.
How similar studies have performed: Other research has shown promise in using similar viral approaches to enhance cancer immunotherapy, indicating potential for success in this novel application.
Where this research is happening
Evanston, United States
- Endeavor Health Clinical Operations — Evanston, United States (Active)
Researchers
- Principal investigator: Xu, Weidong — Endeavor Health Clinical Operations
- Study coordinator: Xu, Weidong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.